Beta-blockers will continue to fall out of favor for hypertension

January 2013

Beta-blockers will continue to fall out of favor for hypertension...especially atenolol.

Beta-blockers seem to prevent fewer CV events in patients with hypertension than other BP meds...despite similar BP lowering.

Atenolol has a particularly bad reputation...because most hypertension trials evaluating cardiovascular risk used atenolol.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Drug Interactions more alerts for drug and grapefruit interactions
Natural Medicines new Rx Vascepa (vas-EE-puh, icosapent ethyl) will compete with Lovaza and fish oil supplements for lowering triglycerides
OTC Products new warnings about the potential dangers of energy drinks and "shots"
Cardiology Beta-blockers will continue to fall out of favor for hypertension
Osteoporosis Binosto (BIN-oss-tow), a new alendronate effervescent tab for osteoporosis
Benzodiazepines Is it okay to COMBINE benzodiazepines
Psychiatry more use of corticosteroids and less use of antivirals to treat Bell's palsy
Antithrombotics Aspirin will be used to PREVENT recurrent venous thromboembolism
Antithrombotics when to stop antiplatelet drugs or anticoagulants before surgery
Oral Health what works for canker sores or aphthous ulcers
Generics 2013 will be another big year for first-time generics.